The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Abstract Background Cardiac steatosis is an early yet overlooked feature of diabetic cardiomyopathy. There is no available therapy to treat this condition. Tyrosine kinase inhibitors (TKIs) are used as first or second-line therapy in different types of cancer. In cancer patients with diabetes mellit...

Full description

Bibliographic Details
Main Authors: Yue Gu, Elisa Avolio, Valeria V Alvino, Anita C Thomas, Andrew Herman, Poppy J Miller, Niall Sullivan, Ashton Faulkner, Paolo Madeddu
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Cardiovascular Diabetology
Subjects:
Bone marrow
Cardiac function
Dasatinib
db/db mouse model
Diabetic cardiomyopathy
Bone marrow-mesenchymal stem cells
Online Access:https://doi.org/10.1186/s12933-023-01955-9

Internet

https://doi.org/10.1186/s12933-023-01955-9

Similar Items